西南医科大学学报2024，Vol.47Issue(4)：316-320,5.DOI:10.3969/j.issn.2096-3351.2024.04.008
和厚朴酚逆转非小细胞肺癌紫杉醇耐药的作用及机制
Effect and mechanism of honokiol in reversing paclitaxel resistance in NSCLC
摘要
Abstract
Objective This study aimed to explore the potential of Honokiol in reversing paclitaxel resistance and to understand its underlying mechanisms in non-small cell lung cancer(NSCLC).Methods Using the non-small cell lung cancer cell line A549 and the paclitaxel-resistant cell line A549T as research subjects,A549T cells were divided into the control group,Honoliol group,Pacli-taxel group and Honokiol+Paclitaxel group.Cells of Honoliol group and Paclitaxel group were treated with a certain concentration of Honoliol or Paclitaxel respectively,while the cells of Honokiol+Paclitaxel group were treated with these two drugs.We assessed the ef-fects of honokiol on Paclitaxel-resistant cell line A549T using various methods including MTT assay,flow cytometry,cell immunofluo-rescence assay and Western blot analysis.Results When honokiol was combined with paclitaxel to intervene with A549T cells cultured in vitro,the cell survival rate was significantly reduced compared to the control group;after honokiol intervention with A549T cells cul-tured in vitro,the number of cells in the G2/M phase increased,and the expression level of P-glycoprotein(P-gp)was decreased com-pared to the control group.Conclusion Honokiol could reverse the paclitaxel resistance of A549T cells cultured in vitro,and its mecha-nism was related to the inhibition of P-glycoprotein(P-gp)expression levels and the reduction of drug efflux.关键词
和厚朴酚/非小细胞肺癌/紫杉醇/多药耐药/P-糖蛋白Key words
Honokiol/Non-small lung cancer(NSCLC)/Paclitaxel/Multidrug resistance/P-glycoprotein分类
医药卫生引用本文复制引用
戴曦,唐大春,袁竞,余文静..和厚朴酚逆转非小细胞肺癌紫杉醇耐药的作用及机制[J].西南医科大学学报,2024,47(4):316-320,5.基金项目
四川省自然科学基金项目(2022NSFSC0729) （2022NSFSC0729）
西南医科大学附属医院科研项目(19039,17180) （19039,17180）
